Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Pfizer 4Q Revenues up 105% | Contract Pharma

What are you searching for?

Sign in
Financial News

Pfizer 4Q Revenues up 105%

Comirnaty contributes $12.5 billion in direct sales and alliance revenues in the quarter and $36.8 billion for the year.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Pfizer
4Q Revenues: $23.8 billion (+105%)
4Q Earnings: $3.4 billion (earnings were $847 million 2Q20)
FY Revenues: $81.3 billion (+95%)  
FY Earnings: $22.0 billion (earnings were $9.2 billion FY20)
Comments: Biopharmaceuticals Group sales were $23.5 billion in the quarter, up 107%, driven by vaccine sales of $13.9 billion, up from $2.0 billion in 2Q20. Oncology sales were $3.2 billion, up 7% in the quarter. Internal Medicine sales were down 3% to $2.2 billion. Hospital sales were $1.9 billion in the quarter, up 1%. Inflammation & Immunology sales were down 3% to $1.2 billion. Rare Disease sales were $950 million, up 10%. Pfizer CentreOne revenues were $382 million, up 24%, reflecting growth from manufacturing of legacy Upjohn products for Viatris and certain Comirnaty-related manufacturing activities performed on behalf of BioNTech. 
 
Comirnaty contributed $12.5 billion in direct sales and alliance revenues in the quarter, and and $36.8 billion for the year. Eliquis sales were up 19% in the quarter. Biosimilars grew 30% operationally to $680 million, driven by recent oncology monoclonal antibody biosimilar launches of Ruxience (rituximab), Zirabev (bevacizumab) and Trazimera (trastuzumab), as well as growth from Retacrit (epoetin). Vyndaqel/Vyndamax sales were up 34% operationally. Paxlovid contributed $76 million in U.S. sales after FDA EUA in late-December 2021. Xeljanz sales were up 4%.
 
Prevnar family sales were down 25% operationally. Chantix continues to be negatively impacted by the ongoing global pause in shipments due to the presence of N-nitroso-varenicline above an acceptable level of intake set by various global regulators. Ibrance in the U.S., down 7%. Sutent sales were down 32% due to loss of exclusivity. Premarin sales in the U.S. were down 31%. R&D expenses were $5.9 billion in the quarter, up 76%.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters